Skip to main content
Premium Trial:

Request an Annual Quote

What GWAS Can't Tell Us (Yet)

A post at Mailund on the Internet reviews the common disease/common variant hypothesis of genome-wide association studies, and considers whether or not it's true. He points to a review article recently published in PLoS Genetics, which claims that so far, GWAS haven't been able to prove that common diseases are, in fact, caused by a few common variants (versus many rare variants). Mailund sums up the paper, arguing for more GWAS with larger sample sizes: " ... with the sample size we have used so far, we do not really have the power to detect the rare variants that would tell us if the common disease/common variant hypothesis is true or not."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.